What diseases does Avapritinib treat and what is its marketing status?

Avatinib is a targeted tyrosine kinase inhibitor that targets multiple mutated forms of KIT and PDGFRA receptors, demonstrating strong potential for targeted therapy in specific types of solid tumors and hematological diseases. Its indications are wide, covering gastrointestinal stromal tumor (GIST), advanced systemic mastocytosis (AdvSM) and indolent systemic mastocytosis (ISM), providing clear clinical benefits to patients.

In the field of gastrointestinal stromal tumors, avatinib is indicated for the treatment of adult patients with unresectable or metastatic PDGFRA exon 18 mutations (including PDGFRA D842V mutations). By highly selectively inhibiting the PDGFRA kinase activity of this mutant isoform, avatinib can block its abnormal signaling, thereby effectively controlling tumor growth and prolonging patient survival.

In addition to solid tumors, avatinib has also shown significant efficacy in the treatment of advanced systemic mastocytosis. This is a rare hematopoietic system disease characterized by excessive proliferation of mast cells in bone marrow, liver, spleen and other tissues, and releasing large amounts of mediators to cause multi-organ damage. Avatinib targets the D816V mutated KIT protein, which is present in most patients with advanced systemic mastocytosis and is closely associated with disease progression. By inhibiting abnormally activated KIT signaling, avatinib can significantly reduce mast cell load, improve organ function damage and clinical symptoms, and improve patients' quality of life.

In addition, avatinib has shown potential in the treatment of indolent systemic mastocytosis. Used in small doses, the drug can relieve symptoms and is particularly effective in controlling mediator-related symptoms. This provides new treatment options for patients with indolent systemic mastocytosis.

Regarding marketing status, avatinib was developed byBlueprint Medicines and has received regulatory approval in multiple countries and regions. The U.S. Food and Drug Administration (FDA) first approved the drug in January 2020 for the treatment of GIST patients carrying PDGFRA exon 18 mutations, becoming the first targeted therapy drug for this mutation type indication. In June of the following year, the FDA further approved it for the treatment of advanced systemic mastocytosis. In May 2023, the FDA re-approved avatinib as the first drug to treat indolent systemic mastocytosis. In Europe, the drug has also received conditional approval from the European Medicines Agency (EMA) for patients with corresponding mutations.

In mainland China, avatinib is availableIt was approved for marketing by the National Medical Products Administration (NMPA) in 2021, bringing new treatment hope to patients with GIST and systemic mastocytosis in China. This approval marks the widespread application and recognition of avatinib worldwide, and also reflects China's continuous progress and development in the field of cancer treatment.

Reference materials:https://www.drugs.com/pro/ayvakit.html